ATE401097T1 - Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung - Google Patents

Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung

Info

Publication number: ATE401097T1
Authority: AT; Austria
Prior art keywords: imidazocinolinamines; adjuvants; dna vaccination; vaccination; dna
Prior art date: 2000-09-20

Application number

AT01967535T

Other languages

English (en)

Inventor

Lindy Louise Thomsen

Peter Topley

John Philip Tite

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-20

Filing date

2001-09-20

Publication date

2008-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401097(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-09-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE401097T1 publication Critical patent/ATE401097T1/de

Links

238000011238 DNA vaccination Methods 0.000 title 1
239000002671 adjuvant Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT01967535T 2000-09-20 2001-09-20 Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung ATE401097T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0023008.6A GB0023008D0 (en)	2000-09-20	2000-09-20	Improvements in vaccination

Publications (1)

Publication Number	Publication Date
ATE401097T1 true ATE401097T1 (de)	2008-08-15

Family

ID=9899764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01967535T ATE401097T1 (de)	2000-09-20	2001-09-20	Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung

Country Status (24)

Country	Link
US (3)	US20040076633A1 (de)
EP (1)	EP1318835B1 (de)
JP (1)	JP2004509150A (de)
KR (1)	KR100876263B1 (de)
CN (1)	CN1197620C (de)
AR (1)	AR035586A1 (de)
AT (1)	ATE401097T1 (de)
AU (2)	AU8790801A (de)
BR (1)	BR0113982A (de)
CA (1)	CA2422863A1 (de)
CZ (1)	CZ2003792A3 (de)
DE (1)	DE60134866D1 (de)
ES (1)	ES2309086T3 (de)
GB (1)	GB0023008D0 (de)
HU (1)	HUP0301180A3 (de)
IL (1)	IL154947A0 (de)
MX (1)	MXPA03002453A (de)
MY (1)	MY138978A (de)
NO (1)	NO20031274L (de)
NZ (1)	NZ524792A (de)
PL (1)	PL360895A1 (de)
TW (1)	TWI287453B (de)
WO (1)	WO2002024225A1 (de)
ZA (1)	ZA200302231B (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
AU2003216851B2 (en) *	2002-03-19	2008-04-17	Powderject Research Limited	Imidazoquinoline adjuvants for vaccines
GB0206461D0 (en) *	2002-03-19	2002-05-01	Glaxo Group Ltd	Improvements in vaccination
US20050266024A1 (en) *	2002-03-19	2005-12-01	Powdermed Limited	Adjuvant
WO2004032829A2 (en) *	2002-08-15	2004-04-22	3M Innovative Properties Company	Immunostimulatory compositions and methods of stimulating an immune response
JP2006513212A (ja)	2002-12-20	2006-04-20	スリーエムイノベイティブプロパティズカンパニー	アリール／ヘタリール置換されたイミダゾキノリン
US7731967B2 (en)	2003-04-30	2010-06-08	Novartis Vaccines And Diagnostics, Inc.	Compositions for inducing immune responses
WO2005018556A2 (en) *	2003-08-12	2005-03-03	3M Innovative Properties Company	Hydroxylamine substituted imidazo-containing compounds
CA2536249A1 (en) *	2003-08-25	2005-03-10	3M Innovative Properties Company	Delivery of immune response modifier compounds
US20050048072A1 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
RU2006105101A (ru)	2003-08-27	2007-10-10	3М Инновейтив Пропертиз Компани (US)	Арилокси и арилалкиленокси замещенные имидазохинолины
WO2005023190A2 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for cd5+ b cell lymphoma
US7544697B2 (en)	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
US8871782B2 (en)	2003-10-03	2014-10-28	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
US8598192B2 (en) *	2003-11-14	2013-12-03	3M Innovative Properties Company	Hydroxylamine substituted imidazoquinolines
CA2545774A1 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
AR046781A1 (es)	2003-11-25	2005-12-21	3M Innovative Properties Co	Derivados de imidazoquinolinas. composiciones farmaceuticas.
WO2005066170A1 (en) *	2003-12-29	2005-07-21	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) *	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005228150A1 (en) *	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) *	2004-06-15	2005-12-29	3M Innovative Properties Company	Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) *	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) *	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009832A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Substituted imidazo ring systems and methods
US8026366B2 (en) *	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
JP2008515928A (ja) *	2004-10-08	2008-05-15	スリーエムイノベイティブプロパティズカンパニー	Ｄｎａワクチンのためのアジュバント
DE102004049223A1 (de) *	2004-10-08	2006-04-20	Johannes-Gutenberg-Universität Mainz	Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1819364A4 (de) *	2004-12-08	2010-12-29	3M Innovative Properties Co	Immunmodulatorische zusammensetzungen, kombinationen und verfahren
JP2008526765A (ja) *	2004-12-30	2008-07-24	スリーエムイノベイティブプロパティズカンパニー	皮膚転移の処置
AU2005326708C1 (en)	2004-12-30	2012-08-30	3M Innovative Properties Company	Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1831226B1 (de) *	2004-12-30	2012-08-08	3M Innovative Properties Company	Chirale tetracyklische verbindungen, die interferon biosyntheze induzieren
AU2006210392A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
CA2597587A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943636B2 (en)	2005-04-01	2011-05-17	3M Innovative Properties Company	1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006107853A2 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
CA2620182A1 (en)	2005-08-22	2007-03-01	Dennis A. Carson	Tlr agonists
ZA200803029B (en) *	2005-09-09	2009-02-25	Coley Pharm Group Inc	Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006287270A1 (en) *	2005-09-09	2007-03-15	Coley Pharmaceutical Group, Inc.	Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ES2429170T3 (es)	2005-11-04	2013-11-13	3M Innovative Properties Company	1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
EP1988896A4 (de)	2006-02-22	2011-07-27	3M Innovative Properties Co	Konjugate zur modifizierung von immunreaktionen
US8329721B2 (en) *	2006-03-15	2012-12-11	3M Innovative Properties Company	Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US8088788B2 (en)	2006-03-15	2012-01-03	3M Innovative Properties Company	Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
CA2645832A1 (en) *	2006-04-25	2007-11-01	Intercell Ag	Hcv vaccinations
US20090060928A1 (en) *	2006-05-26	2009-03-05	Jean-Claude Bystryn	Topical Toll Like Receptor Ligands as Vaccine Adjuvants
US8846697B2 (en)	2006-05-31	2014-09-30	The Regents Of The University Of California	Purine analogs
US20100129403A1 (en)	2006-06-20	2010-05-27	Transgene S.A.	Recombinant viral vaccine
CA2655933C (en)	2006-06-23	2014-09-09	Alethia Biotherapeutics Inc.	Polynucleotides and polypeptide sequences involved in cancer
US7906506B2 (en) *	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
CN100450484C (zh) *	2006-10-11	2009-01-14	北京科信必成医药科技发展有限公司	一种咪喹莫特混悬溶液及其凝胶剂
EP2510946B1 (de)	2007-02-07	2015-08-05	The Regents of The University of California	Konjugate synthetischer TLR-Agonisten und Verwendung dafür
CN101657213B (zh) *	2007-02-15	2014-02-26	曼康公司	用于增强t细胞应答的方法
WO2009018465A1 (en)	2007-07-31	2009-02-05	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Vaccination with killed but metabolically active (kbma) protozoans with toll-like receptor agonists
AU2008335457B2 (en)	2007-12-07	2015-04-16	Glaxosmithkline Biologicals S.A.	Compositions for inducing immune responses
CN104829714A (zh)	2008-11-03	2015-08-12	阿莱斯亚生物疗法股份有限公司	特异性地阻滞肿瘤抗原的生物活性的抗体
WO2010088924A1 (en)	2009-02-06	2010-08-12	Telormedix Sa	Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2508190B1 (de) *	2009-12-03	2021-06-02	Aureo Co., Ltd.	Makrophagen-phagozytose-aktivierende zusammensetzung und/oder zusammensetzung zur förderung der zytokinproduktion in makrophagen
CN101850117B (zh) *	2010-06-03	2012-05-30	国家兽用生物制品工程技术研究中心	一种复方免疫佐剂及疫苗
DK2606047T3 (en)	2010-08-17	2017-03-27	3M Innovative Properties Co	COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
CA2893376A1 (en)	2011-03-31	2012-10-04	Alethia Biotherapeutics Inc.	Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
EP3153180A1 (de)	2011-06-03	2017-04-12	3M Innovative Properties Company	Heterobifunktionale binder mit polyethylenglykolsegmenten und daraus hergestellte immunantwort-modifizierende konjugate
BR112013031028A2 (pt)	2011-06-03	2016-11-29	3M Innovative Properties Co	conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
AU2013209234B2 (en)	2012-01-09	2017-11-09	Adc Therapeutics Sa	Method for treating breast cancer
GB201310578D0 (en)	2013-06-13	2013-07-31	Univ Nottingham Trent	Electroactive actuators
WO2015023649A2 (en)	2013-08-12	2015-02-19	3M Innovative Properties Company	Peptides for enhancing transdermal delivery
JP7145757B2 (ja)	2015-10-12	2022-10-03	リフローメディカルインコーポレイテッド	突出する薬剤送達フィーチャーを有するステント、ならびに、関連のシステムおよび方法
EP3445761A1 (de)	2016-04-19	2019-02-27	Innate Tumor Immunity, Inc.	Nlrp3-modulatoren
WO2017184735A1 (en) *	2016-04-19	2017-10-26	Ifm Therapeutics, Inc	Nlrp3 modulators
US11697851B2 (en)	2016-05-24	2023-07-11	The Regents Of The University Of California	Early ovarian cancer detection diagnostic test based on mRNA isoforms
TWI674261B (zh)	2017-02-17	2019-10-11	美商英能腫瘤免疫股份有限公司	Nlrp3 調節劑
WO2018217897A1 (en) *	2017-05-23	2018-11-29	David Weiner	Compositions and method for inducing an immune response
KR20200051778A (ko)	2017-09-13	2020-05-13	사노피 파스퇴르	인간 시토메갈로바이러스 면역원성 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL73534A (en) *	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
IL105325A (en) *	1992-04-16	1996-11-14	Minnesota Mining & Mfg	Immunogen/vaccine adjuvant composition
JP2002514056A (ja) *	1996-10-23	2002-05-14	アメリカン・ホーム・プロダクツ・コーポレーション	ワクチン
GB9818627D0 (en) *	1998-08-26	1998-10-21	Glaxo Group Ltd	Improvements in dva vaccination

2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
2001
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en not_active Ceased
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active Expired - Fee Related
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
- 2001-09-20 EP EP01967535A patent/EP1318835B1/de not_active Revoked
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MXPA03002453A (es)	2003-06-19
HK1057700A1 (en)	2004-04-16
MY138978A (en)	2009-08-28
AR035586A1 (es)	2004-06-16
CZ2003792A3 (cs)	2004-12-15
KR100876263B1 (ko)	2008-12-26
NZ524792A (en)	2004-09-24
US20110002953A1 (en)	2011-01-06
DE60134866D1 (de)	2008-08-28
CN1197620C (zh)	2005-04-20
JP2004509150A (ja)	2004-03-25
EP1318835B1 (de)	2008-07-16
PL360895A1 (en)	2004-09-20
GB0023008D0 (en)	2000-11-01
CN1473051A (zh)	2004-02-04
ES2309086T3 (es)	2008-12-16
AU2001287908B2 (en)	2005-06-30
HUP0301180A2 (hu)	2004-03-01
NO20031274L (no)	2003-05-19
AU8790801A (en)	2002-04-02
WO2002024225A1 (en)	2002-03-28
US20040076633A1 (en)	2004-04-22
ZA200302231B (en)	2004-05-05
TWI287453B (en)	2007-10-01
NO20031274D0 (no)	2003-03-19
EP1318835A1 (de)	2003-06-18
BR0113982A (pt)	2003-08-19
HUP0301180A3 (en)	2005-11-28
CA2422863A1 (en)	2002-03-28
KR20040023566A (ko)	2004-03-18
US20070248614A1 (en)	2007-10-25
IL154947A0 (en)	2003-10-31

Legal Events

Date	Code	Title	Description
2009-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60134866D1 (de)	2008-08-28	Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung
DE69928763D1 (de)	2006-01-12	Adjuvanzien zur Verwendung in Impfstoffen
DE60111534D1 (de)	2005-07-21	Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
DE60143301D1 (de)	2010-12-02	Polyarylcarboxamide zur verwendung als lipidsenker
NO20031483L (no)	2003-05-28	Vaksine
NO20026175L (no)	2003-02-26	Vaksinesammensetning
NO20024172L (no)	2002-11-01	Vaksine
EP1418940A4 (de)	2006-09-20	Dna expressionsvektoren und verwendungsverfahren
DE60101147D1 (de)	2003-12-11	Mikroprozessor beständig gegen eine energie-analyse
EP1424392A4 (de)	2004-11-24	Neue sekretionsproteine und dna dafür
DE60126814D1 (de)	2007-04-05	Inhalation von stickoxid
DE60136400D1 (de)	2008-12-11	Reinigung von hbv-Antigenen zur Verwendung in Impfstoffen
DE50107834D1 (de)	2005-12-01	Dispergierung von pigmenten in polyolefinen
NO20033882L (no)	2003-10-31	Vaksine
EP1369101A4 (de)	2004-07-28	Kosmetisches w/ö/w-emulsionspräparat
ATA192799A (de)	2001-10-15	Neue verwendung von antikörpern als impfstoffe
DE60112148D1 (de)	2005-09-01	Verwendung von (Per)fluoroetherverbindungen als Zusatzstoffe in Formulierungen zur Holzbehandlung
EP1446130A4 (de)	2006-04-05	Ehrlichia-canis-gene und -impfstoffe
EP1293568A4 (de)	2005-10-26	Protein und dessen dns
DK1328289T3 (da)	2008-12-15	Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36
DE60007360T2 (de)	2004-10-07	Amorphe modifikation von torasemid
DE50010237D1 (de)	2005-06-09	Verwendung von pit-emulsionen in fermentationsverfahren
EP1490396A4 (de)	2006-04-19	Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe
NO20030821D0 (no)	2003-02-21	Gener og proteiner, og deres anvendelse
ATA2152001A (de)	2004-08-15	Verwendung von selenhältigen präparaten